A Phase 1, Randomized, Open-Label, 2-Period, Crossover Design Study to Assess the Effects of Multiple Oral Doses of Lansoprazole, Dexlansoprazole, Omeprazole or Esomeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Subjects.

Trial Profile

A Phase 1, Randomized, Open-Label, 2-Period, Crossover Design Study to Assess the Effects of Multiple Oral Doses of Lansoprazole, Dexlansoprazole, Omeprazole or Esomeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Clopidogrel; Dexlansoprazole; Esomeprazole; Lansoprazole; Omeprazole
  • Indications Acute coronary syndromes; Dyspepsia; Gastritis; Gastro-oesophageal reflux; Myocardial ischaemia; NSAID-induced ulcer; Peptic ulcer; Peripheral arterial occlusive disorders; Stroke; Thrombosis
  • Focus Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 06 Sep 2011 Actual initiation date changed from Jan 2010 to Dec 2009 as reported by ClinicalTrials.gov.
    • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
    • 05 Apr 2011 Results presented at the 60th Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top